DARIEN, Conn. & BURLINGTON, Mass.--(BUSINESS WIRE)--The Vascular Care Group (“TVCG”) and Mangrove Management Partners (“Mangrove”, the affiliated management company of TVCG), announced today that Dr. Paul Gagne, will assume an expanded leadership role as Chief of Clinical Operations and Research. In this capacity, Dr.

康涅狄格州达里恩（DARIEN）和马萨诸塞州伯灵顿（BURLINGTON），马萨诸塞州（BUSINESS WIRE）——血管护理集团（“TVCG”）和红树林管理合作伙伴（“红树林”，TVCG的附属管理公司）今天宣布，保罗·加涅（Paul Gagne）博士将担任临床运营和研究负责人的扩大领导角色。在这个职位上，博士。

Paul Gagne will further lead and enhance clinical operations and research initiatives, with a strong focus on improving standardization of care and clinical outcomes..

保罗·加涅（PaulGagne）将进一步领导和加强临床操作和研究计划，重点关注改进护理标准化和临床结果。。

Dr. Paul Gagne is an internationally recognized expert in the field of vascular surgery, including with respect to venous disease. A pioneer in vascular surgery research and innovative treatments, Dr. Gagne previously served as the Director of the Vascular Research Laboratory at New York University Hospitals Center.

Paul Gagne博士是血管外科领域（包括静脉疾病）的国际公认专家。作为血管外科研究和创新治疗的先驱，加涅博士曾担任纽约大学医院中心血管研究实验室的主任。

Dr. Gagne is also the founder of Vascular Breakthroughs, an innovative clinical trials platform advancing life-changing vascular disease treatments through multiple active clinical trials. In 2013, Dr. Gagne became the first surgeon in the State of Connecticut to implant a drug-eluting stent to reopen a blocked artery in the thigh of a person with peripheral artery disease.

加涅博士也是血管突破的创始人，这是一个创新的临床试验平台，通过多项积极的临床试验推进改变生命的血管疾病治疗。2013年，加涅博士成为康涅狄格州第一位植入药物洗脱支架以重新打开外周动脉疾病患者大腿阻塞动脉的外科医生。

He has been an innovator and leader in the diagnosis and treatment of deep vein disease that leads to complications of chronic venous hypertension..

他是导致慢性静脉高压并发症的深静脉疾病诊断和治疗的革新者和领导者。。

In his extended role, Dr. Paul Gagne will provide strategic leadership to optimize clinical workflows, enhance patient outcomes, and drive innovative research efforts while ensuring standardization of high-quality patient care. He will be instrumental in fostering a culture of continuous improvement, promoting collaboration among medical professionals, and maintaining ethical standards in clinical research..

保罗·加涅（PaulGagne）博士（Dr.Paul Gagne）将在其扩展角色中提供战略领导，以优化临床工作流程，提高患者预后，并推动创新研究工作，同时确保高质量患者护理的标准化。他将有助于培养持续改进的文化，促进医学专业人员之间的合作，并在临床研究中保持道德标准。。

'We are excited to announce Dr. Gagne's expanded role as Chief of Clinical Operations and Research,' said Mark Rowe, CEO of Mangrove Management Partners. 'His outstanding track record and unwavering commitment to excellence in patient care and innovation align perfectly with our mission. Dr. Paul Gagne's leadership will play a pivotal role in advancing our vision, improving patient outcomes, and demonstrating the positive impacts to patients and the healthcare system by providing rapid access to innovative therapies in office-based settings.'.

红树林管理合作伙伴首席执行官马克·罗（MarkRowe）说，我们很高兴宣布加涅博士扩大了临床运营和研究主管的职位他出色的业绩记录以及对卓越患者护理和创新的坚定承诺与我们的使命完美契合。Paul Gagne博士的领导将在推进我们的愿景，改善患者预后以及通过在办公室环境中快速获得创新疗法来证明对患者和医疗保健系统的积极影响方面发挥关键作用。”。

Dr. Gagne is eager to embrace these added responsibilities, stating, 'I am honored to take on this extended role within The Vascular Care Group and Mangrove and to contribute to the advancement of vascular surgery, standardization of high-quality care, and improving patient outcomes. I look forward to collaborating with our dedicated staff to drive innovation and ensure the highest standards of care.'.

加涅博士渴望承担这些额外的责任，他说：“我很荣幸在血管护理小组和红树林承担这一扩展的角色，并为血管外科的进步、高质量护理的标准化和改善患者预后做出贡献。我期待着与我们敬业的员工合作，推动创新，确保最高标准的护理。”。

About Mangrove Management Partners

关于红树林管理合作伙伴

Mangrove Management Partners is a healthcare practice management and technology platform company focused on changing the paradigm of the delivery of care with a specialized focus on the treatment of vascular disease. We form long-term affiliations with vascular providers through a unique model that aligns interests with physicians, management, and the hospitals we serve—in order to optimize the delivery of care and to deliver value: better clinical outcomes at a lower cost.

红树林管理合作伙伴是一家医疗保健实践管理和技术平台公司，专注于改变护理模式，专注于血管疾病的治疗。我们通过独特的模式与血管提供者建立长期联系，该模式将与医生，管理层和我们服务的医院的利益联系起来，以优化护理的提供并提供价值：以较低的成本获得更好的临床结果。

Mangrove is relentlessly focused on safety, compliance, innovation, and best practices across the spectrum of clinical care and business management, and our affiliated physicians are committed to serving the communities in which they live and work. To learn more, visit www.mangrovemp.com..

红树林一直专注于临床护理和商业管理领域的安全、合规、创新和最佳实践，我们的附属医生致力于为他们生活和工作的社区服务。欲了解更多信息，请访问www.红树林管理网。。

About The Vascular Care Group

关于血管护理小组

The Vascular Care Group (TVCG) is a growing group practice committed to the prevention, diagnosis, and treatment of vascular disease including both arterial and venous conditions. The practice brings together decades of expertise among a team of vascular specialists offering unparalleled care at several vascular centers in New England, including in Maine, Connecticut, and Massachusetts.

血管护理小组（TVCG）是一个不断发展的团体实践，致力于预防，诊断和治疗血管疾病，包括动脉和静脉疾病。该实践汇集了数十年来血管专家团队的专业知识，在新英格兰的几个血管中心提供无与伦比的护理，包括缅因州、康涅狄格州和马萨诸塞州。

TVCG’s comprehensive services range from non-invasive vascular testing to complex vascular surgeries, including a full spectrum of minimally invasive endovascular procedures performed in-office and open surgical care at affiliated hospitals. TVCG is dedicated to innovation in the vascular space and is an active leader in clinical trials, extensively participating in studies of cutting-edge technologies through its affiliated clinical trials management organization.

TVCG的综合服务范围从非侵入性血管检测到复杂的血管手术，包括在办公室进行的全方位微创血管内手术和附属医院的开放手术护理。TVCG致力于血管领域的创新，是临床试验的积极领导者，通过其附属的临床试验管理组织广泛参与尖端技术的研究。

More information about the practice can be found at https://vascularcaregrp.com/..

有关该做法的更多信息，请访问https://vascularcaregrp.com/..